A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth.
Int J Cancer
; 125(2): 483-7, 2009 Jul 15.
Article
in En
| MEDLINE
| ID: mdl-19330834
ABSTRACT
Earlier we generated novel derivatives of the hydroxamate-based histone deacetylase inhibitor (HDACi), Oxamflatin (Ox), which demonstrate considerable HDACi activity. Here the effects of one such derivative, Metacept-1 (MCT-1), alone or in combination with tamoxifen on mammary tumour growth have been assessed in a syngeneic orthotopic model. MCT-1 alone resulted in a trend towards inhibition of growth of 4T1.2 mammary tumours. Since the combination of MCT-1 and tamoxifen up-regulates estrogen receptor expression in 4T1.2 cells in vitro, we tested this combination and found a significant reduction in primary tumour growth over tamoxifen treatment alone. Taken together, these observations suggest that the novel HDACi MCT-1 may warrant further exploration in the treatment of estrogen receptor positive breast carcinoma, particularly when used in combination with conventional agents such as tamoxifen.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tamoxifen
/
Cell Division
/
Antineoplastic Agents, Hormonal
/
Enzyme Inhibitors
/
Histone Deacetylase Inhibitors
/
Mammary Neoplasms, Experimental
Limits:
Animals
Language:
En
Journal:
Int J Cancer
Year:
2009
Document type:
Article
Affiliation country:
Australia